Dr. Clay Siegall is the co-founder of Seattle Genetics where he now serves as the company’s president, chairperson of the Board of Managers and the Chief Executive Officer. He holds a Ph.D. in Applied Genetics from the George Washington University. Dr. Clay is a degree holder of Zoology from the University of Maryland. Before becoming the co-founder of the Seattle Company, Dr. Siegall worked with two research institutes. The two research institutes were National Institute of health from 1988 to 1991 before joining the Bristol-Myers Squibb from 1991 and 1997.
Dr. Clay Siegall is currently a member of the Board at Alder Biopharmaceuticals, which is a biotechnology company under private ownership. Through the years, Dr. Siegall has written over 70 publications and is holds 15 patents. As a scientist, Dr. Siegall has helped build and grow the Seattle Genetics Company through scientific research, innovations, and the development of drugs. Also, the company has promoted its name throughout the country through its passion for helping patients.
Under the leadership of Dr. Clay Siegall, the Seattle Genetics company has been able to build a different pipeline of cancer therapies that are based on the antibodies. For example, the ADCETRIS which even received accelerated authorization from the FDA (Food and Drug Administration). Through his management, the company is now the leading in the development of ADC for the treatment of cancer. The doctor has also led capital-raising strategies, which have resulted to securing of millions of dollars for Seattle Genetics Company via private and public financing.
Siegall has received honors and awards when he has been working at the Seattle Genetics Company. In the year 2012, he received an award from the Pacific Northwest Ernst & Young as the ‘entrepreneur of the year.’ Also, in 2013 he was recognized as the Alumnus for the year for mMath, Natural Sciences, and Computer. Dr. Clay Siegall has focused his attention on developing cancer therapies that would help in prevention and treatment of the disease.